THE US Food and Drug Administration (FDA) has said it is considering labeling changes to include additional ocular inflammatory conditions for three immune checkpoint inhibitors.
Changes would affect Bristol-Myers Squibb's Yervoy (ipilimumab), Opdivo (nivolumab) and Merck's Keytruda (pembrolizumab), the FDA said.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jul 17